A pilot case-control study of second or third-line treatment with cetuximab-containing chemotherapy (cetux-chemo) in patients (pts) with metastatic colorectal cancer (mCRC) who were previously treated with cetux-chemo
Invited conference paper presented and published in conference proceedings


引用次數
替代計量分析
.

其它資訊
摘要Background: This study hypothesized that: (1) pts who had prior exposure to Cetuxchemo in the treatment of mCRC followed by a chemo-break, would respond to retreatment with Cetux at progression (PD), & that the overall response rate (ORR) would be better than those who are treated with chemo alone.

Methods: This study consisted of 2 cohorts. Cohort 1: Prospectively enrolled pts with KRAS-wild type mCRC who had prior Cetux-chemo in 1st/ 2nd line with a best ORR of SD/PR/CR followed by a chemo-break, were re-treated with Cetux-chemo at PD. Cohort 2: A retrospective cohort of KRAS-WT patients (matched by age, sex, no. of sites of metastases (mets), prior Cetux-chemo and prior surgery) who received chemo without any targeted therapy at PD following a chemo-break. The primary objective was to compare the overall response rate (ORR) of cohort 1 & 2, secondary objectives included disease control rate (DCR) & progression free survival (PFS).

Results: 22 eligible pts were enrolled in cohort 1 across two centers in Hong Kong: median age 58yrs, M:F ratio¼ 1:1; site of metastases (mets) ¼ solitary 36.3%, > 1 site 63.7%. None had prior bevacizumab; prior Cetux as 1st line ¼ 77.3% & as 2nd line ¼ 22.7%. In 21 evaluable pts, ORR ¼ 52.4%, SD 33.3%, PD 14.3% & DCR 85.7%. The median OS for cohort 1 ¼ 18.6 ms (95% CI: 11.1-27.1) & 1-yr PFS 36.4%. In cohort 2, 22 matching KRAS-WT patients were identified. The ORR for cohort 2 ¼ 31.8%, DCR 50%, median OS 11ms (95% CI: 4.5-17.1) & 1-yr PFS 22.7%. In a regression analysis which included other prognostic variables (age, sex, prior no. of line of chemo, no. of sites of mets), DCR was the only significantly different factor (odd ratio, OR 6.0, 95% CI: 1.365-26.371, p ¼ 0.018) favouring cohort 1. There was a non-significant trend favouring cohort 1 in ORR (52.4% vs 31.8 %, p ¼ 0.171) and median PFS (8.1ms vs 5.3ms, p ¼ 0.524).

Conclusions: The data suggests that in pts who had prior Cetux-chemo in the 1st or 2nd line treatment of mCRC, re-introduction of Cetux-chemo following a chemo-break was effective in most patients
出版社接受日期30.06.2018
著者Ho CS, Cheng AC, Li L, Ho WM, Hui EP, To KF, Tong JHM, Ma BBY
會議名稱European-Society-for-Medical-Oncology Asia Congress
會議開始日23.11.2018
會議完結日25.11.2018
會議地點Singapore
會議國家/地區新加坡
會議論文集題名Annals of Oncology
出版作品名稱ANNALS OF ONCOLOGY
出版年份2018
月份11
卷號29
期次Suppl 9
出版社OXFORD UNIV PRESS
文章號碼108P
頁次35 - 35
國際標準期刊號0923-7534
電子國際標準期刊號1569-8041
語言英式英語
Web of Science 學科類別Oncology;Oncology

上次更新時間 2020-31-05 於 02:28